STOCK TITAN

Endexx Initiates TPD Registration in Europe

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Endexx Corporation (EDXC): HYLA Targets 11 Key European Markets With TPD
Positive
  • HYLA's non-nicotine products are gaining market share in European markets
  • The TPD registration opens the European market to all HYLA's products
  • The E-Cigarettes market is projected to generate global revenues of US$24.6 billion in 2023
Negative
  • None.

HYLA Targets 11 Key European Markets With TPD

CAVE CREEK, AZ, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Endexx® Corporation (OTCQB: EDXC), a provider of innovative plant-based wellness and nutritional products, today announced that its HYLA division has completed preliminary review of its premium vegan formulated traditional e-cigarette products. Hyla is filing its TPD application in Europe. TPD is (The “Tobacco Products Directive” (2014/40/EU) which aims to improve the functioning of the internal market for tobacco and related products, while ensuring a high level of health protection for European citizens.)

The demand for the HYLA non-nicotine products is quickly gaining market share in the initial markets in Europe. Hyla’s distributors and potential clients in European markets are asking management at HYLA to add a high quality and fully compliant traditional nicotine product line, in addition to Hyla’s non-nicotine  products.

“Our proprietary botanical ingredient profile, flavoring, and vegan sensitive formulations created in the United States will carry through in HYLA’s nicotine enhanced products. These factors are what differentiate HYLA’s product quality,” stated Nick Mehdi, CEO of HYLA. Mr. Mehdi added, “Hyla’s distribution partners in Europe are the top tobacco and e-cigarette distributors in Europe and have directly requested this product expansion due to ongoing demand and need for compliance leadership provided by HYLA.”

The TPD registration accelerates HYLA’s product placement into these European countries: Austria, Belgium, Czech Republic, France, Germany, Greece, Italy, Slovakia, Spain, Switzerland and the United Kingdom. Several of the listed countries have already reviewed HYLA’s non-nicotine products. The TPD registration completely opens the European market to all HYLA’s products.

According to the source *Statista:

  • The E-Cigarettes market is projected to generate global revenues of US$24.6 billion in 2023.
  • It is anticipated to experience an annual growth rate of 3.61% (CAGR 2023-2028) on a global scale.
  • Among all countries, the United States leads in terms of revenue generation, with an estimated revenue of US$8.3 billion in 2023.
  • In 2023, the revenue in the E-Cigarettes market in Northern Europe amounts to US$399.2m.
  • Comparing globally, the United States generates the highest revenue in this segment, reaching US$8.2 billion in 2023.
  • When considering the population, the per capita revenue in Northern Europe is estimated at US$13.25 per person in 2023 vs. US$3.81 per capita in the US Market.

“Endexx’s investment into HYLA has generated early success by providing non-nicotine electronic devices into the international markets. The HYLA brand represents high quality, vegan, and natural products, with attention to all regulations and compliance required to conduct commerce in each country,” said Todd Davis, CEO Endexx. “This registration process helps secure the success of our long- term target of being a dominant player in the international age-restricted CPG markets.”

www.endexx.com & www.cbdunlimited.com 

www.tryhyla.com

About Endexx Corporation

Endexx Corporation develops and distributes all natural, plant-derived wellness products and topical skincare products.  Its products vary from balms, creams, lotions, butters, masks, scrubs, and oils, all with the shared purpose of healthy skin and grooming wellness.  The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and support of skin health. www.endexx.com

Hyla currently markets its proprietary botanical non-nicotine, guarana and L-Dopa-based vape products in a wide variety of flavors. The Hyla device is the first non-nicotine vape product to be produced in this manner in the United States and provides an unprecedented 4,500 puffs per device. Hyla is currently being distributed in 10 countries and has signed distribution agreements with an additional nine countries. Due to recent customer demand, Hyla is now expanding its botanical product line of vapes to include nicotine versions in certain international markets where the product is regulated and allowed for sale. 

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

We caution that any forward-looking statements (as such term is defined in the U.S. Private Securities Litigation Reform Act of 1995) contained in this press release or made by us, our management, or our spokespeople involve risks and uncertainties and are subject to change based on various factors, many of which are beyond our control. Accordingly, our future performance and financial results may differ materially from those expressed or implied in any such forward-looking statements. Forward-looking statements include, without limitation, statements regarding our future operating results, the implementation and impact of our strategic plans, and our ability to meet environmental, social, and governance goals. Words such as “estimate,” “commit,” “target,” “goal,” “project,” “plan,” “believe,” “seek,” “strive,” “expect,” “anticipate,” “intend,” “potential” and any similar expressions may identify forward-looking statements. Risks associated with the following factors, among others, could affect our financial performance and cause actual results to differ materially from those expressed or implied in any forward-looking statements.

Except as may be required by law, we assume no obligation and do not intend to make publicly available any update or other revisions to any of the forward-looking statements contained in this press release to reflect circumstances existing after the date of this press release or to reflect the occurrence of future events, even if experience or future events make it clear that any expected results expressed or implied by those forward-looking statements will not be realized. More information on potential factors that could affect our results is included “Risk Factors” in our amended Annual Report on Form 10-K/A filed with the Securities and Exchange Commission on June 9, 2023.

No Offer or Solicitation . This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.  No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, and, where applicable, the requirements under the securities laws of any other applicable jurisdiction.

For further information, please contact:
Endexx Corporation:
IR@Endexx.com
https://endexx.com/investors/
480-595-6900

*Source: Statista


FAQ

What is the TPD application in Europe for HYLA's products?

The TPD application refers to the 'Tobacco Products Directive' (2014/40/EU), aiming to improve the functioning of the internal market for tobacco and related products while ensuring a high level of health protection for European citizens.

Which European markets is HYLA targeting with its products?

HYLA is targeting Austria, Belgium, Czech Republic, France, Germany, Greece, Italy, Slovakia, Spain, Switzerland, and the United Kingdom.

What is the projected revenue of the E-Cigarettes market in 2023?

The E-Cigarettes market is projected to generate global revenues of US$24.6 billion in 2023, with an annual growth rate of 3.61% (CAGR 2023-2028).

What is the focus of HYLA's products?

HYLA's products are high quality, vegan, and natural, with attention to all regulations and compliance required to conduct commerce in each country.

ENDEXX CORP

OTC:EDXC

EDXC Rankings

EDXC Latest News

EDXC Stock Data

4.94M
474.28M
6.34%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Cave Creek